

ADENOSINE DEAMINASE (ADA) FL

AD F080 CH

4 x 20 ml

INTENDED USE

Reagent for quantitative in vitro determination of adenosine deaminase in biological fluids (serum) and intended as aid to diagnosis of tuberculous pleurisy and ADA severe immunodeficiency disease.

The IVD device can be used both in manual or on automatic analyzers. The product is intended for professional use in clinical laboratories.

TEST PRINCIPLE

ADA enzyme converts adenosine to inosine, which starts a sequence of enzymatic reactions mediated by PNP (Purine Nucleoside Phosphorylase) and XOD (Xanthine Oxidase), leading to hydrogen peroxide (H₂O₂). This compound reacts with TOOS (N-Ethyl-N-(2-hydroxy-3-sulfo-propyl)-3-methylaniline) in the presence of peroxidase, to form a quinone compound. Absorbance increase per unit time, measured at 546, is proportional to the concentration of ADA in the sample¹⁻³.

MATERIALS PROVIDED AND COMPOSITION

ADA R1 F080: 4 x 16 ml (liquid) blue cap

Composition: Phosphate buffer, PNP > 1 KU/l, XOD > 1 KU/l, POD > 1 KU/l, 4-AAP (4-Aminoantipyrine) > 1 mM, stabilizer and preservative.

ADA R2 F080: 1 x 16 ml (liquid) red cap

Composition: Phosphate buffer, adenosine > 5 mM, TOOS > 1 mM, stabilizers and preservative.

NOT SUPPLIED REQUIRED MATERIALS

Appropriate laboratory instrumentation. Spectrophotometer UV/VIS fitted with thermostatic cuvette holder. Automatic micropipettes. Glass or high quality polystyrene cuvettes. Saline solution.

REAGENT PREPARATION

Use ready-to-use reagents.

STORAGE AND STABILITY

Store all kit components at 2-8°C, away from direct light sources.

Stability of reagents: up to expiration date claimed on label storing at 2-8°C;

Stability after first opening of reagent bottle: preferably within 60 days storing at 2-8°C.

PRECAUTIONS

ADA R1: It is not classified as hazardous.

ADA R2: It is not classified as hazardous.

Follow required safety procedures when handling all laboratory reagents.

SPECIMEN

Serum.

Samples are stable for one week when stored at 2-8°C⁴.

PROCEDURE

| | | |
|--|----------|--------|
| Wavelength: | 546 nm | |
| Lightpath: | 1 cm | |
| Temperature: | 37°C | |
| dispense: | standard | sample |
| reagent R1 | 1 ml | 1 ml |
| standard | 25 µl | - |
| sample | - | 25 µl |
| Mix, incubate at 37°C for 5 minutes. | | |
| dispense: | standard | sample |
| reagent R2 | 250 µl | 250 µl |
| Mix, after 3 minutes read the absorbance against water, by incubating at 37°C. Perform other two readings at 60 seconds intervals. Calculate the ΔA/min. | | |

RESULTS CALCULATION

Serum:

$$ADA\ U/l = \frac{\Delta A/\min_{(sample)}}{\Delta A/\min_{(standard)}} \times \text{Standard value}$$

REFERENCE INTERVALS

Adults⁵: ≤ 14.0 U/l

Each laboratory should establish appropriate reference intervals related to its population.

QUALITY CONTROL AND CALIBRATION

Calibration is required with each change in reagent lot number. It is suggested to verify calibration with at least one level of an internal quality control. If control results fall outside acceptable ranges, recalibration may be necessary. For this purpose the following human based control sera are available:

QUANTINORM CHEMA - MULTINORM CHEMA

with normal or close to normal control values

QUANTIPATH CHEMA - MULTIPATH CHEMA

with pathological control values.

If required, a calibrator is available:

ADA CALIBRATOR

Please contact Customer Care for further information.

TEST PERFORMANCE

Sensitivity / Limit of Detection (LOD)⁶

The method is able to detect up to 0.50 U/l.

Analytical specificity:

Interferences⁷

interference does not occur in the presence of:

| | |
|---------------|--------------|
| hemoglobin | ≤ 500 mg/dl |
| bilirubin | ≤ 36 mg/dl |
| Intralipid | ≤ 1600 mg/dl |
| ascorbic acid | ≤ 5 mg/dl |

Veridicity⁸

BIAS% < 10.54

Accuracy:

Trueness⁹

Total observed error% < 16.7 (allowable total error)

Precision⁹

Repeatability

| intra-assay (n=10) mean (U/l) | SD (U/l) | CV% |
|-------------------------------|----------|------|
| sample 1 | 13.1 | 0.22 |
| sample 2 | 34.9 | 0.32 |

Reproducibility

| inter-assay (n=20) mean (U/l) | SD (U/l) | CV% |
|-------------------------------|----------|------|
| sample 1 | 13.2 | 0.41 |
| sample 2 | 34.9 | 0.53 |

Measurement range¹⁰

2.01 - 200.0 mg/dl

Linearity¹⁰

the method is linear up to 200 U/l.

If the limit value is exceeded, it is suggested to dilute sample 1+9 with saline and to repeat the test, multiplying the result by 10.

Methods comparison⁹

a comparison between Chema and a commercially available product gave the following results:

Serum:

$$\begin{aligned} \text{Adenosine Deaminase (ADA) FL Chema} &= x \\ \text{Adenosine Deaminase competitor} &= y \\ n &= 112 \end{aligned}$$

Linear regression

$$y = 1.006x - 1.045\ U/l \quad r = 0.9992$$

Passing-Bablok¹¹⁻¹²

$$y = 0.947x - 0.284\ U/l$$

WASTE DISPOSAL

P501: Dispose of product according to national/international regulations.

NOTICE TO THE USER

Any serious accident involving the device must be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is located.

REFERENCES

1. H. Delacour, C. Sauvanet et al. Analytical performances of the Diazyme ADA assay on the Cobas 6000® system. *Clinical Biochemistry*. 2010; 43: 1468-1471.
2. X. Gui, and H. Xiao. Diagnosis of tuberculous pleurisy with adenosine deaminase (ADA): a systematic review and meta-analysis. *Int. J. Clin. Exp. Med.* 2014; 7(10): 3126-3135.
3. E. Azimi, F. Zarei et al. Adenosine deaminase (ADA) activity and isozymes in the serum of patients with hepatitis B compared with healthy people: a useful method in diagnosis clinical status. *Archives of Medical Laboratory*

Sciences. 2017; 3(1): 15-20.

4. G. Giusti Adenosine Deaminase. *Method of Enzymatic Analysis*. 1974; 18(3): 252-254.

5. S. Afrasiabian et al. Diagnostic value of serum adenosine deaminase level in pulmonary tuberculosis. *J. Res. Med. Sciv.* 2013; 1092-1099.

6. K. Klaus, M.D. Bandilla et al. Reactivity of Rheumatoid Factor with Autologous IgG Antibodies. *Arthritis and Rheumatism*. 1969; 12 (2): 74-81

7. W. Ehret, F. da Fonseca-Wollheim et al. Use of anti-coagulants in Diagnostic Laboratory investigations 2002; WHO/DIL/LAB/99.1 Rev. 2.

8. E. Theodorsson, B. Magnusson et al. Bias in Clinical Chemistry. *Bionalysis* 2014; 6(21): 2855-2875.

9. CLSI EP17-A:2004 Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline.

10. M. Vidali, M. Tronchin et al. Protocollo per la comparazione di due metodi analitici di laboratorio. *Biochimica Clinica* 2016; 40(2): 129-142.

11. H. Passing and W. Bablok. A New Biometrical Procedure for Testing the Equality of Measurements from Two Different Analytical Methods. *J. Clin. Chem. Biochem.* 1983; 21: 709-720.

12. L. Bilić-Zulle. Comparison of methods: Passing and Bablok regression. *Biochemia Medica* 2011; 21(1) 49-52.

MANUFACTURER

Chema Diagnostica Srl
Via Campania 2/4
60030 Monsano (AN) - ITALY - EU
phone +39 0731 605064
fax +39 0731 605672
e-mail: mail@chema.com
website: http://www.chema.com

SYMBOLS

Chema Diagnostica uses symbols listed in the ISO 15223-1 (see www.chema.com - Section "Products" for definition of symbols used).

Addition, deletions or changes are indicated with a vertical line on the side of the affected paragraph.

IUS-7.5 EN rev. n. 2 date 12/01/2022

